Dr Sarah Howell
CEO at ARECOR THERAPEUTICS PLC
Replay available
Final Results Results for the year ended 31 December 2024 hosted by Arecor Therapeutics (LSE:AREC) on Investor Meet Company, held 2025-05-01.

On 6ix: 6ix.com/event/arecor-therapeutics-plc-arec-final-results-results-for-the-year-ended-31-december-2024
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:02 Good afternoon, ladies and gentlemen, and welcome to the ARECOR THERAPUITIX PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the Q and A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and we'll publish those responses where it's appropriate to do so on the Investor Meet company platform. And before we begin, we would just like
0:32 to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the executive management team from ARECOR THERAPUITIX PLC. Sarah, good afternoon. Good afternoon. Thank you. And so good afternoon, everybody. Thank you for taking the time to join us today. And as you know, my name is doctor Sarah Howell. I'm the CEO of ARECOR THERAPUITIX, and I'm joined today, by with David Ellum, who's our chief financial officer. So today, we're going to talk you through our results and for the year ending the 12/31/2024. So I'll draw your attention to our customary legal notice. So I think probably most people on the the line today, I'm sure I will have spoken to previously and you would have heard me present, but I'd like to just take the opportunity to allow David to introduce himself. Many of you may have seen that David joined us as interim CFO back in November of last year. I'm very pleased to confirm he's now joined us permanently as our chief financial officer. So, David, if I could just hand over to you to to give a brief brief introduction of yourself, please.
1:44 Thank you, Sarah. And just a very brief introduction. Good to meet everybody. I have been, probably in biotech for about twenty five years, quite a few of those as CFO. And and just as per the the blurb on the sheet, some of the, more relevant roles, our CFO Science Therapeutics when it was aim listed before it went to Nasdaq for a few years. I was CFO at Juvenescence Limited, which is a private company you may have come across, which is into the field of longevity and has many subsidiaries in many different areas of medicine. And then before both of those, I was a regional CFO at BioMarin Pharmaceutical when the company was on a huge growth trajectory in Europe, between 2010 and 2016.
2:36 So, look forward to speaking with you today. Thanks, David.
2:42 So, just as a a recap really here. So, at ARECOR, we're very much focused on transforming patient care by bringing enhanced therapeutics to markets that reduce patient burden whilst improving their outcomes. And we do this by leveraging our innovative and proprietary formulation technology platform, Aristat, to develop novel formulations of existing therapeutics with these enhanced properties. We're very much targeting areas where there's significant unmet patient needs in high value markets, either ourselves through our clinical stage proprietary pipeline within the diabetes and obesity space or via our partnerships with major pharma and biotech companies.
3:27 All of these areas I'll I'll talk about obviously in more detail today. So we have existing growing revenue streams from our partnerships and also high value creation potential across our proprietary pipeline. So just looking very briefly across our portfolio here. So we have a very broad and derisked product portfolio of both these partnered programs where we're agnostic to therapeutic area, but also our in house proprietary products, which are based in the diabetes space with our insulin, assets that are in clinical development and also within diabetes and obesity space where we're looking at the oral delivery of peptides with our first target molecule there being oral GLP one. And, again, I'll I'll talk about all of these areas in much more detail.
4:16 So that's just really a snapshot snapshot of our pipeline as it stands today. So if we go now to looking at operational highlights, this also includes post period events. So starting with our diabetes and obesity pipeline, we had stellar results in twenty twenty four for our lead insulin candidate, a t two seven eight. So this is a highly concentrated, five times concentrated, very rapid acting insulin. And why this study was so key here is that we went head to head with the best two insulins that were available for this particular patient population. So NovoRapid is a rapid acting insulin from Novo Nordisk. And the only other highly concentrated insulin, which is a Humulin R u five hundred, so a five times concentrated five five hundred unit per mil insulin.
5:07 So same concentration as a t two seven eight from Eli Lilly. What was really important here is this clinical study was in type two diabetic patients with high body mass index. So these were, overweight to obese type two diabetics. And why this is important is that this is they are a particularly difficult patient population to treat. They tend to have be the most out of control with their diabetes and have the highest blood glucose levels here. So really looking for improved treatment options for this patient population. And we'll talk more about the patient need and the commercial opportunity, there for AT two seventy eight as well. We're also making significant progress towards striking a strategic partnership with the further developments and commercialization of a t two seven eight, and we see the most value for a t two seven eight to patients and and to and commercially in the insulin pump setting. And, again, I'll talk much more today around that, patient need and the commercial value potential for AT two seventy eight. Now our other insulin in clinical development is AT two forty seven. So this is a standard concentration insulin. It's a hundred units per mil.
6:22 Again, we have clinical data across two clinical studies in type one diabetic patients here showing superiority compared to the best insulins available today. And at the moment, that clinical data is being modeled by, a number of insulin pump companies, so these device companies. And what they're looking at here is with their, algorithms and they have these very sophisticated in silico models that they are assessing with the improved and superior kinetics of a t two four seven. So, you get more insulin on board faster and a a better glucose lowering profile. How much can they use that to improve time in range for this patient population. And that's really critical towards lowering the burden, improving, outcomes.
7:11 That's all being funded by the device companies, and we'll expect to see data coming out of that during the second half of this year. And then within the oral delivery of peptide space, we've selected oral GLP one, as our first, model compound here. We've made significant initial progress. We've overcome the first initial challenges here of stabilizing the peptide, GLP-one as a peptide within our oral delivery matrix. And now we're working towards conducting a series of nonclinical. So these are animal pharmacokinetic studies. So looking at the bioavailability, so the uptake of the drug post dosing. And we'll be performing a series of these through the second half of twenty twenty five, which will inform our next development steps there.
7:57 And, again, we'll talk about that in more detail. Across our partner portfolio, of course, as you'll know, there is a biosimilar product, AT two twenty. This is on the market. It's being launched globally by our partner under a royalty generating, license agreement with ARECOR, and that's generating growing royalty streams under this license. And we would expect to see those to continue to grow across 2025 and beyond, particularly as the major markets come on board there. And David will talk about that in a little bit more detail later. And we have a growing portfolio of both licenses. We entered into a new exclusive milestone and royalty bearing license agreement for ready to use medicine, at the end of twenty twenty four.
8:43 And you may note that we've entered into two additional prelicensed partnerships so far in 2025. So these have significant upside potential in the future if they convert to these milestone and royalty bearing agreements. Across our intellectual patent portfolio here, this is really the lifeblood of the company. Of course, it both protects our ARISTAT technology platform, but also those enhanced formulations of existing therapeutics that we develop using the platform. We had 15 key patents granted across 2024. We've had a further two, granted so far this year, including increased protection and grants across our proprietary diabetes portfolio, so AT two forty seven and AT two seventy eight, which is critical, of course, to protect the commercial interests of those products and also driving our partnering licensing model with major pharma and biotech companies.
9:44 So I'm going to move to talking a little bit more detail around our insulin, products that we have in clinical development. So just taking a step back and a really high level view, as we talked about, eighty two four seven is a standard concentration. So it's a hundred unit per mil ultra rapid acting insulin. The target here is really around with eighty two four seven having superior kinetics. So it's the fastest acting insulin in development today, has the potential to enable what we call a fully closed loop system here, sometimes known as the artificial pancreas here. So this is an automated insulin delivery system. And this is around lowering burden for the patient population. So almost, being able to apply your pump and your algorithms and your CGM and then and forget about it and not have to interact with the system whilst you're wearing that, whilst improving outcomes.
10:39 And this is really around improving this timing range. So it's the time that the, patient or person with diabetes is spending within a healthy target blood glucose range. So very much a a product targeted at the type one patient population. Now for AT two seventy eight, we're really excited about AT two seventy eight. It's very unique, insulin. It's the only very highly concentrated, so five times the standard concentration, but ultra rapid acting insulin. So physiologically, if you concentrate up insulin and you don't do anything special, which is what we've done here, you would see, a very slow acting insulin. And I'll show you some clinical data here as well that demonstrates that. So, you would see a slow uptake of insulin and a delayed glucose lowering profile there. So that has an impact on outcomes.
11:32 We've overcome this with the Aristat technology. So we have this very ultra rapid acting profile. And the key here is that AT two seventy eight is the only insulin here that can enable that next innovation leap within the insulin pump setting. So it's very much drive in a patient pool and a strategic drive from the insulin device companies here, the pump companies, to move towards a longer wear systems that currently warn the standard of care is three days to move to seven days plus and also make these, pumps as small as possible here. Now if you want to, have longer wear pumps and you want them to be much smaller, you need to get much more insulin on board within these systems. So you do need a highly concentrated insulin.
12:19 And I'll talk about some of the, the market opportunity around that and so the numbers of patients that this would be applicable, to shortly. So this is very much enabling people with diabetes with high daily insulin needs to transition across to insulin pump systems. There's a whole wealth of data and real world data out there showing that people with diabetes do better on pumps. But despite this and particularly for the type two patient population where the average daily dose or the daily need of insulin is around a hundred units a day, less than ten percent of them are currently using insulin pump systems because they're simply not practical for them to use today because of their very high insulin needs.
13:05 So I'm just going to do a very quick recap of the AT two seventy eight and phase one clinical data. So this is our type two diabetics with high BMI. So we were comparing a t two seven eight, which you see, in the yellow here with NOVA RAPIDS. So that's Novo's hundred unit per mil insulin. It commands about half of the mealtime insulin market today. So these are all mealtime insulins in the blue. And then Lily's concentrated insulin is Humulin RU five hundred in the purple. And you're looking at the pharmacokinetic data here. So this is essentially the absorption of insulin or how much insulin you're getting on board over time and post a single injection here. And what you can see here is that we see a shift to the left for a t two seven eight. So this is essentially showing us that we get more insulin on board faster. We're accelerating the absorption post injection, and we're getting much more insulin on board much faster than NovoRapid.
14:06 And as you can see, a very traumatic, difference compared an improvement compared to the only other concentrated insulin and Humulin RU five hundred. And then if we look at the pharmacodynamic data, so this is essentially the glucose lowering profile. We've seen from the previous data that we got more insulin on board faster and this translated directly across to the pharmacodynamic data. So this shows us that we're getting insulin on board, but we're also lowering blood glucose much faster than, the two best insulins that are available for this patient population today. So it really confirms our previous data that we have for AT two seven eight in type one diabetic patients where we also saw superiority that AT two seven eight has the potential to be the insulin of choice whether you have type one diabetes, type two diabetes, and irrespective of your BMI.
15:03 Now I spoke earlier around the type two patient population and how less than ten percent of them are using insulin pumps today. And some of the reason why, that is is shown in these heat maps here. So what you're looking at here is, on the left hand side, the units are what the current insulin pumps that are on the market today, how much insulin that they can hold using the current insulins that are on the market today. So they can hold between a hundred and eighty to three hundred units of insulin. And then we map this against the total total daily insulin need for type two diabetic population. This is US based data here. And what you can see is that for the standard of care of three days between 60 and around sixty and eighty five percent depending on which pump they're using, a type two diabetics can't even achieve three day wear, so it's simply totally impractical for them.
16:03 And if we're moving towards seven day wear systems or even further miniaturization, then almost all of the type two patient population are unable to get to seven day wear plus. So this shows us here and there's a significant unmet need for a much more concentrated but very faster acting insulin. As you see on the bottom, $827.08 to 500 unit per mil insulin. All type two diabetics would be able to get to three day wear, and the vast majority of them would be able to get to seven day wear. But this is not just a type two problem here. We also see this to a lesser extent, but still significant across the type one patient population. Again, the same, theory here except the date is mapped against the total daily dose for type one diabetics in The US. And as you can see here, you know, if we're looking at current three day wear, they're broadly served, you know, and and these pumps can broadly address their needs.
17:05 But moving towards seven day wear, again, you have between sort of sixty and nearly eighty five percent of type one diabetics as well today cannot achieve seven day wear. And a real ask and a pull from that patient population is to have smaller devices. They want smaller body worn devices because it's a very visible indicator of the fact that you've got chronic conditions. So if you miniaturize the devices, you can get less insulin on board or less volume of insulin on board. So this really exacerbates this issue. And we're very much seeing if you look publicly what the insulin device companies, pump companies are saying now, they're all they're all talking strategically around longer wear systems, miniaturized pumps, and transitioning type two diabetics over to their insulin pumps because this is a significant upside opportunity, of course, for them.
18:03 So taking that now and translating into that, what does that look like in terms of addressable market opportunity here? So, again, this data is based on The US only at this point. So there's some upside opportunity that I'll talk about. So it's the initial addressable market for AT 278. And what we've looked at is essentially two, patient segments here. The first is people with diabetes with high total daily dose needs. So we we have the cutoff here of greater
18:34 than a hundred units a day. So for this patient population, as we've just seen, current insulin pumps are not accessible for them. Almost all of them can't make that to three day wear now. So they're using multiple daily injections because there's no pump system that can match their total daily needs. And there's around just over a million of these, about one point one million of this patient population in The US today. And then we look at also the people with diabetes that are on insulin pump therapy, so they've transitioned across but would switch to a a t two seven eight insulin pump combination product to be able to access seven day wear.
19:19 And and there's around a million of those patients in The US today. So if we take this patient population and their average daily insulin need and multiply that by the insulin net price per unit. So it's 5¢ per unit in The US, and this is incorporating all discounts, rebates, the IRA, etcetera. Here, that gives us a total addressable insulin revenue market of just under $3,000,000,000 per annum here. And, of course, there there would be significant additional upside commercial potential here. If you miniaturize those pumps, that further exacerbates and drives the need, and and broadens that addressable patient population for a t two seven eight and, of course, also commercializing a t two seven eight in an insulin pump outside of The US as well.
20:17 So in terms of next steps for a t two seven eight, the next development steps, we've been doing a lot of work both in combination with a team of ex FDA, reviewers there from the diabetes division and also the insulin pump companies themselves to really map out what's the, most accelerated
20:38 development pathway to market whilst, of course, generating the data to demonstrate the superiority of the products and outcomes for the patient population, which would, drive its uptake in the market. We will be going to the FDA. We'll be filing, a what's called a type c. It's essentially a scientific advice meeting to the FDA, during this quarter, there, and that's to really talk about the clinical study design and that interaction with the pump and the further development pathway to market. And we'll expect to gain feedback from the FDA within the second half of the year, which will ultimately lead us into a position of being able to file for approval for this clinical study. So currently, we're assuming this is a phase straight into phase two clinical study. So it's accelerated development here, and we'd be looking at, comparing again with NovoRapid or NovoLog as it's called in The US, in this, high insulin need patient population.
21:39 So we'll be really confirming and generating that key time and range data, but also looking at the precision, accuracy, and safety of dosing a very highly concentrated insulin over a continuous period of time. This would be a six week study in the patient population. So really pivotal and key clinical study. So I'm just going to move and tack now and talk a little bit more about the oral delivery of peptides here. So, I mean, just taking again perhaps a a step back, peptides generally are an increasingly important class of therapeutics. There are over 800, peptides now in development, and over a 100 of those are within the diabetes and obesity space.
22:28 But there are only two marketed orally delivered peptides on the market. And this is because the oral delivery of peptides is extremely challenging, and that's due to their molecular characteristics here leading to very low bioavailability. So that's the post dosing, the amount of active drug that is still active and has survived through the pretty harsh GI tract. Now one of those products that's on the market today is a product called Rybelsus. It's from Novo Nordisk. It's an oral GLP one.
23:02 And this product is on the market. It's doing very well. They Novo reported sales last year of 3,400,000,000, but it has a very low bioavailability. It has less than 1% bioavailability. So there's real opportunity here to further enhance and improve that product, to enhance that bioavailability, to bring it up above that 1%. It also has a, because of where it's released and its dosing, has a pretty strict dosing criteria that has to be dosed on an empty stomach. So we'd be looking to circumvent that, as well here. But perhaps more importantly here, this is around if we can develop a technology approach, know, oral delivery approach for oral GLP one and show enhanced bioavailability, that allows us to expand this platform out more broadly to peptides as a class of therapeutics, which is a huge opportunity given the numbers of peptides in development, but also the real patient pool for orally delivered medicines because of their convenience, that leads to better adherence and compliance, which, leads to better outcomes.
24:16 So there's a real drive and pull towards, oral delivery of peptides. In terms of status, as I mentioned earlier, we've had initial very positive results from the first formulation development phase. So the first significant challenge we needed to overcome was to stabilize the peptide within the oral delivery matrix that we were that we are using because it was very unstable there. So we've overcome that challenge. And as I mentioned, during the course of the second half of the year, we'll be focused on further optimizing those formulations to enhance that bioavailability, And we'll be generating that data, throughout the course of the second half of this year, which will then define our next development steps. But if it's successful here with oral GLP one, it really does open up a huge opportunity to expand into this growing class of therapeutics.
25:11 And maybe just before I hand over to David, just to talk a little bit more about what's going on in this space. There's been a huge amount of deal making in the oral delivery space, here. This is across the board. This is just a snapshot of most relevant and most recent deals. We have a spreadsheet that's running into many pages now of of deal making in this space, and it's combinations of m and a, investments, flooding into the space as well as pharma and big pharma acquiring companies and also licensing, taking license rights to technology platforms. The most recent was last week, actually, a company called Cipramed who have a pretty early in development oral peptide delivery platform. It's at nonclinical stage. They have nonclinical data akin to the data that we'll be generating through the second half of the year. And Merck had taken out a nonexclusive global, license and rights to that, platform.
26:15 I mean, it's a buy books deal here, so it's it's around $500,000,000, and we don't know the split there in terms of upfronts and and downstreams. But it's it's a significant deal for a preclinical stage platform. There's no clinical data yet, against their oral delivery platform. So it really shows you that, there's an opportunity lots of opportunity here, and big pharma are also prepared to move and take risk, quite early in development profiles. So I'm just going to hand over to David to talk through the financials.
26:55 Thank you, Sarah. So just some comments on some of the key extracted financials on the on the page in front. So revenues rose 11%, and that was due to an increase in products sold through Tetris. But I think more interestingly, a nice bump in the royalty income from 8220. On the r and d expenses, we dropped from 5.4 last year to 3.0. And although a chunk of that was reduction in clinical study costs after the eighty two seven eight study completed. We also had a naught £400,000 reduction in payroll costs,
27:38 and that will that will continue and annualize through into 2025. The s g and a expenses are flat at 6.2, but worth mentioning that within that 6.2, 2,800,000 of that related to the Tetris operation. And in 2025, we see that number as more than halving. So certainly at least a reduction there of 1,500,000 in the s g and a expenses going forward. The exceptional items, the 3,300,000, that was the impairment of assets relating to Tetris, and that was covered in the January press release. And then at the bottom, the cash and investments, 3,300,000, and that was boosted during the year by the successful summer fundraise.
28:26 So I think that the message in these key financials is that we've entered 2025 well positioned to focus on the two core areas of high value, the ultra concentrated and rapid acting insulin 8002 and '78 partnered with medical device companies and the oral development of peptides platform. Those are the two key areas. And in addition to that, the 2025 cessation of activities at Tetris will be cash generative. You can see in finance review that came out that the operating cash flow of $9,200,000 last year, 3,200,000 of that was Tetris, and we expect Tetris to be positive this year. And in addition, we have the partner revenues will continue to grow. So the AT two twenty royalty, we're excited about. We're pleased with the commercial traction that the partner is making, and we look forward to seeing that increase.
29:21 And then lastly, we have the cost reductions already mentioned. And, actually, our headcount from December 23 until today has decreased by 32%, showing a commitment to cash conservation that, as I mentioned, will annualize and that will continue to impact on our bottom line. So I think that these measures, with the runway well into h one twenty six, they will position ARECOR to focus our cash and our people on striking that partnership for a t two seven eight and to allow for the next stages in the oral delivery of peptides platform, which are the areas we have identified as having the greatest value to shareholders. Thank you. Thanks, David.
30:07 So, just to round up, today, I'm really just looking towards the future a little bit more here as well and what to look out for. I think, as I mentioned, we're making a very positive progress towards striking a strategic partnership deal with multiple potential partners very much focused on eighty two seven eight in the insulin pump setting here to bring this product to market where you see that very significant unmet patient need and commercial market opportunity there. So a real opportunity to return significant value to shareholders. Of course, for the oral delivery of peptides starting with the GLP one, there'll be the series of preclinical pharmacokinetics, so PK studies throughout the second half of, 2025.
30:59 And with positive data there, we can leverage that to expand to that additional peptides, which we see as a significant upside opportunity for the company. And as David mentioned, we have grown revenue streams here from marketed products 8220. So those are the royalty streams, but also the additional pharma partnerships, both licensed and pre licensed partnerships that we have in place here. So again, growing existing revenue streams, but that really significant upside potential across our proprietary pipeline where we're very much focused on addressing unmet patient needs in large markets. So that draws, the formal presentation aspect of today to a close, but, we'll be very happy to take questions. I'm just seeing some questions that have been coming through, so we'd be happy to work through those and and answer those.
31:59 Perfect. Sarah, David, if I may just jump back in there. Thank you very much indeed for your presentation this afternoon. Ladies and gentlemen, please do continue to submit your questions just by using the Q and A tab that's situated on the right hand corner of your screen. But just while the team take a few moments just to review those questions that have been submitted already, I just like to remind you that a recording of this presentation along with a copy of the slides and the published Q and A can all be accessed via your investor dashboards. Sarah, David, as you can see there, we have received a number of questions that were both pre submitted ahead of today's event as
32:30 well as those that have made their way through throughout your presentation this afternoon as well. So firstly, thank you to all of those on the call for taking the time to submit their questions. And, guys, at this point, if I may just hand back to you just to read out those questions and give your responses where it's appropriate to do so. If And I pick up from you at the end, that'd be great. Thank you. Sure. No problem. And I'm not quite sure why, but as I'm going through the questions, it's leaving the slides. So, I don't know whether the slides can be taken down, but, otherwise, just ignore the slides. So the first question is quite long, so I'm going to summarize it a little bit. So it's really a question around creating shareholder value. It's around the
33:13 share price, which has dropped since the IPO in July 21. And, also, really a question around what when are we going to achieve those value inflection points and essentially return value to shareholders over the coming few years. So, I mean, I think really here and hopefully as we've talked through the presentation today,
33:43 we're really focused and really clear across the leadership and the board at ARECOR of where we're focusing. And we're focusing on areas where there's opportunity to return transformational value to the business and then, of course, to our shareholders and really focused on these across our proprietary pipeline, two key areas. So eighty two seven eight, and as you've seen with the data that we received in 2024,
34:13 And really, the market dynamics there with the insulin pump companies very much, requiring a highly concentrated rapid acting insulin. So real opportunity there for deal making that, again, can help us retain and grow value and return that value to shareholders as well as the oral delivery of peptides now. The latter is, scientifically challenging, so there's risk there. But, actually, it's a formulation challenge, which is very much in ARECOR's wheelhouse, which is why we believe we have a great opportunity there to be able to deliver something that's not been achieved to date. Of course, the public markets are frustrating. There's no doubt about that. But I think as as everybody can see, ARECOR's ARECOR is not alone at the moment in terms of of shareholder share price movements and particularly across the AIM markets. It doesn't mean we're happy about it.
35:08 But for us, what we can do and what's within our control is to really focus on delivering on the areas that can return that significant value to the business, and we would then fully accept expect that to be reflected in the value of the company.
35:25 So the next question. So as I note that Merck has recently signed a $493,000,000 deal with CypriMed for non exclusive access to their technology that aims to deliver oral peptides with superior bioavailability. Can we have a brief comparison of that platform against Aristat in terms of pros and cons for achieving that goal and perhaps comment on why Merck have chosen CypriMed rather than ARECOR as a partner. I'll take this one, David. And so the you know, I guess, first of all, starting with SIPRIMED, I mean, I agree. Really interesting deal, as I mentioned during the presentation here. Interesting to ask because of the early nature in a sense of the data of the technology platform here. So Cipramed have
36:22 used their approach across a number of peptides, and they've generated, some improvements in bioavailability, in nonclinical animal models. So these these animal PK models. So they've got to for some peptides, not all, around three to 4%. So single digits, not 34% for some peptides here, and that's we can see that from their intellectual property platform. They have been around and doing this for quite some time, which will lead on to perhaps the second half of the question, here. So they've been developing this technology and working on these peptides for around seven to eight years, here.
37:08 And they their approach, they're using a combination of what we'd call pretty classic combination of things like protease inhibitors, permeation enhancers, enteric coated capsules to help protect in the GI tract here. So I think the important areas to note for us are that this demonstrates that large pharma are prepared to do large buy book deals on, preclinical data. So they, you know, not necessarily requiring, clinical studies here to demonstrate. In terms of the question of what's different and, you know, what's different with the ARECOR platform platform and how do we think we'll differentiate essentially.
37:54 So what succeeded so far and albeit this is for only two marketed peptides on the market is the use of these permeation enhancers, cipramed are also in using the using these increase the absorption of drug across the biological membranes essentially, so across the intestinal lining. But certainly, the potential of permeation enhancers alone has been exhausted here. So Cipramed are using these permeation enhancers plus some other protective formulation approaches to protect the products in the GI tract. But the field is really crying out for a radical new approach, and I think that's where certainly where ARECOR come in here. So we're using it's quite different to what Supramed are doing and and and the others in this space. We're using novel combinations here of lipids. So these are fats, which with the peptide essentially stabilized inside these lipids as the cargo. So the intention here in our scientific rationale is that we can use these lipids to trigger natural digestion as you would do normally. And we digest fats essentially in lipids and absorption.
39:10 So we're essentially smuggling the peptide across these membranes through natural processes. So it is a novel approach. There's obviously challenges there that we're and formulation challenges that we're working to achieve, but a real opportunity here to have a totally different approach and see a step change in the enhancement of bioavailability here. Why didn't Merck do the deal with us? We don't have any data, PK data yet. You need, you know, a minimum. If you've asked me last year, would Big Pharma do a deal certainly of that magnitude without clinical data, I'd have said highly unlikely. So I think it's quite interesting. And you can see it's because this is a hot space and, you know, pharma doesn't want to miss out that they've come in so early.
39:59 But we need to generate that data. This preclinical PK data is absolutely key. I mean, we started to develop this platform last year. So we are moving at pace. We're not going to take seven to eight years to get to that, of course. So, you know, that's that's where we need to get a data package that we can go out and talk to pharma with. But there's no doubt if we can be successful in this area, there's there's deals to be done and, not insignificant deals clearly to be done in this space. So the next question is, can the company confirm that they are mindful that whilst the company is valued at a market cap of just over 14,000,000, that they're very vulnerable to an unwelcome takeover approach?
40:51 If so, can they outline their plan and time frame to mitigate that risk? You know, obviously, that's that's an interesting question there. You know, we have a very highly experienced adviser supporting the company and board, of course, here who have all the necessary skills and capabilities to appropriately advise us in the event that such scenario arises. And I think as a public company, that's probably all I should say on that question. So the next question is, can you clarify the revenue potential and timeline for the Medtronic and the a t three five one collaborations?
41:43 So so Medtronic starting with Medtronic, obviously, Medtronic, they're largest insulin pump company today. So they're interesting partnership from that perspective as well. And, we partnered with them to develop a novel format of insulin. It's not a t two four seven or a t two seven eight. It's a different insulin that's compatible with the interperitoneal pump. So this is an implanted insulin pump, here. So there's a very specific patient population and a need there, and it's an important program for Medtronic. It's a prelicensed program, so this is under our technology licensing model. So Medtronic is paying for the formulation development that's being conducted at ARECOR.
42:29 And then they'll have an option in the future as we generate those final data packages for a conversion to a license there, and we'd expect that to be alongside our milestone and royalty bearing model there. A t three five one is a little bit different. So that is a license. So that is a ready to use medicine there. Again, it started as a technology partnership here, so the partner paid for the development of the novel formulation that we developed. So this ready to use medicine has subsequently converted the license here. In terms of timeline, at the time of the announcements at the latter end of twenty twenty four, the partner guided there that they expect to file for approval within 2027 within three three years. So that'd be within 2027.
43:24 So from that, we would anticipate product being on the market by 2028. And, again, that's under a milestone and royalty bearing agreement there. And, you know, what I would say is that partner is moving forward at at pace. They're very actively developing that product. So, you know, at the moment, we'd be very confident around those timelines. I'm gonna find a question for you in a minute, David. So the next question is with multiple platform technologies and potential royalty streams, do you see ARECOR ultimately evolving as a licensor model, or will you pursue in house commercialization for certain assets?
44:11 I mean, I think here, you know, ARECOR is very successfully partnered with pharma. We're looking to partner for our insulin products as well as we talked about, and this is around co development and commercialization here. And, you know, I think it's for us, we're, you know, very comfortable in saying that we don't intend to commercialize our insulin products. These are really significant millions of patient populations, large markets, and large global markets, and ARECOR's not going to set up global sales and marketing force here to commercialize insulin. So that's really part of those negotiations here with the potential partners around we'd be looking for them to commercialize, ultimately commercialize the products here. So it's really around doing the right deals and structuring those to return the most value to the business. But I think, you know, we we won't be looking to commercialize ourselves and sell ourselves our existing proprietary portfolio.
45:16 Okay, David. This one is for you. What is the current cash runway will the company need to do a placing soon? Sure. And in the documentation that went out with the RNS within the finance rules review and the going concern that talks about a cash runway to March 26. We're referring here to a cash runway well into half one twenty six on the basis that we did a very conservative cash projection, for the audit, but, actually, we do still have levers that we can pull to extend that that runway. And I guess with regard to the rest of the question, I think the key here is that we believe that we do have time to strike that partnership for an a t two seven eight deal and that we do have time to generate a reasonable amount of data on the oral development of peptides.
46:12 I've been a scientist, like, I can't at this stage say what stage that will be at, but, again, that gives us, another run into, other financial, levers, if we have a success there. Thanks, David. That's probably a nice segue into the next question, which is, which I'll take. Why is it taking so long to sign a deal for AT two seven eight, and how will that deal be structured? I mean, in terms of deal making, obviously, for a t two seven eight here, there's a lot of competitive tension across this ecosystem. So, you know, there are about five or six insulin pump device companies with very viable pumps on the market in The US today here.
47:02 And what we have seen, and I think what is moving very rapidly now, certainly in the last, you know, six months even, is the market dynamics there, and that's moving rapidly in ARECOR's favor here for AT two seven eight. So as I mentioned, we talked about all the pump companies looking at that underpenetrated type two patient population. So through the the kind of latter half of of last year and into this year, two of the three of the large incumbents gained approval for their pumps for type two patient populations. So they did multiple hundreds of patient clinical studies there to generate the data to show their pumps could be used for type twos and showed significant timing range improvements.
47:51 So they this was Insulet and Tandem, and they showed 2015% respectively timing range improvement for type two switching from multiple daily injections to pumps. That's huge. Medtronic are generating their clinical data currently for the type two patient population are anticipating filing for approval soon, and they'd expect approval within 2025. So again, it shows that it's real move strategically towards the type two patient population and also towards longer wear because they're obviously all competing with each other with the same patient population. Then we have the new innovative pump companies coming in who are also then taking market share. So that market's really dynamic, and there's a real need and a drive and much more motivation there to enter into that next innovation leap that we've spoken about. But these these deal structures take time. This is around a combination product, which is quite different in this space. Normally, an insulin is approved on its own. And then separately, the studies are done to show that it can be used in a particular pump, but this will be a combination product. And we're also looking to the partner to be the commercialization partner. So, again, quite a different ecosystem to that today. And for ARECOR, this is around this there's opportunity here in competitive tension.
49:21 There's lots of different deals that could be structured here, whether they be exclusive, semi exclusive, etcetera, and how you work those through, which are all very live discussions and negotiations. And our focus is doing the right deal for ARECOR that generates the most value for the business and, of course, return to shareholders. So they do take time. What I would say is that, you know, we have confidence here that, you know, we will strike a deal for AT two seventy eight. So next question is, could an insulin like product work for peptides? If not, why not? I'm gonna try and answer this. And if I don't answer the question, perhaps if you could put in a clarifying note. So Insulet have a patch pump, basically, for the continuous fusion of insulin there. So perhaps the question is, could peptides be delivered via continuous infusion on a pump?
50:32 In theory, yes. They could do, I think, for those that perhaps if you take a GLP one, if it was continuous infused slowly over the course of the week, would it would it give a better clinical profile? I don't know. People would have to do the studies there. But there are very good injectable products, single injectable products for the GLP ones today. So a kind of wearable patch pump in a sense. I'm not sure there'd be a patient pull for that product necessarily because they would be having to wear this then twenty four seven compared to doing a single injection. Of course, taking a pill, a single pill, much different. People would much prefer to, as we're used to, if we're taking paracetamol, to swallow a pill and not be the medication administered rather than an injection. So that's really where the focus is. But if I haven't answered that question or I've misinterpreted it, then please do feel free to to add another question.
51:34 The next question is, can you outline time frames returning shareholder value, please? One, three, or ten years. I'll I'll maybe start, and then, David, if you want to add anything here. I mean, I I think as we've talked about, there's some very clear, you know, value driving milestones through the course of 2025 and then certainly going into 2026. So they're kind of near term. So we're very much focused on striking strategic partnership for a t two seven eight and, you know, structuring that in the right way, of course, that it generates the most value for ARECOR. So, you know, that's something that we're is live and we're working on now. So we'll be looking to generate value from that in the near to medium term.
52:21 And then the other areas around oral delivery, of course, is dependent on scientifically very challenging. It's dependent on data. But we do have, you know, world leading scientists here. It's a formulation challenge, and that's where we, excel in the formulation space. So, again, it'd be very much data driven there, but there's no doubt in my mind here if and we can see that from deal structures that are out there in the public domain. If successful, you know, there'll be transformational deals to be done there or make my job very easy. The scientists can deliver compelling Right. Data packages there. And then we have the, you know, the underlying core business, of course, that generates and contributes revenue and income, which offsets our r and d costs.
53:12 I don't know, David, if there was anything you wanted to to add to that as well. No. I think that it's with in coming with a biotech hat, you look at things in in stages so that if we when we sign an $827.08 deal, and as Sarah said, we're we're still looking at various ways of doing that, that will create value. Then as we progress down that path, as we hold the phase two, as we get successful results for the phase two, that then creates another value step. Phase three, likewise. Commercial, likewise. And, you know, when it's I think one of the slides talks about the total addressable market for the insulin for us, $2,900,000,000. So anything where we can show that we are targeting a certain percentage of that will again contribute towards step up in value.
54:06 And I think we heard about CyberMed. No human data, no clinical studies. And, again, I can't comment on the exact timing, but, obviously, we're working towards our own data package for that. So if there is a success on that, if there is an announcement, then, again, that would be a nice first step in a pathway that could lead to I was looking at one of the questions. There's all sorts of options. We can license out the technology. We can do our own products, which is, of course, is where you retain much higher value for the for the business and for the share for the shareholders. So there's there's lots of opportunities for us to execute and to gain that sort of success and increase. The actual question was one, three, or ten years, and I think it's across all of those. But, obviously, over time, you hope that the steps get larger.
54:59 Thanks, David. So next question is is the drop primarily due to Agluo? If not, is it technical or admin? Have we effectively exited some technical research? I mean, this slightly predates you, David. I'm happy to take it or if you want to take it. No. It's okay. So I would say that the the headcount drop is is approximately fifty fifty between Tetris and a little bit of head office g and a. And on the other side, we did have some stuff within research, and that came from a decrease in intention on the specialty hospital products division alongside fairly logically as we ceased on the clinical trials. We didn't need a a clinical group of people with an R and D.
55:48 But, of course, if we then start on for AT 278, start further on the phase two and planning for that, then we'll then as part of that, we would increase the R and D headcount so that we've got the right skilled people to manage that clinical study. Sorry, I was going say just to answer that, so we did make a strategic decision last year in that specialty hospital space. So this is in the ready to use medicine space that we would continue to operate in that area but only under paid partnerships there. So we made decisions to stop developing those ready to use medicines ourselves because, actually, that same resource, this you know, is is formulation development, essentially. So it's the same amount of effort to work in ready to use medicine space as it is to work on the oral delivery. But the upside opportunity on oral delivery versus ready to use medicines is significantly different there. And we have entered into partnerships and technology partnerships and most recently licensing as you've seen with AT three fifty one with the ready to use medicines. So we can still generate value there, but we've decided that we're not going to take the you know, have the the people and the financial risk essentially there of investing in that area without a partner. So we'll partner first, and then it will be paid development and
57:19 license upside. I think the last question's for you, David. Are any r and d credits subject to HMRC investigation? Well, thank you for giving me the easiest question. So the answer to that one is is no. In the RNS, I think we stated that the 2023 r and d tax credit claim was filed in April 25, so we expect to hear back from HMRC within a couple of months. But, no, absolutely no no investigation at all. Sarah, David, if I may just jump back in there. Thank you very much indeed for being so generous of your time and addressing all of those questions that came in from investors this afternoon. And of course, if there are any further questions that do come through, we'll make these available to you immediately after the presentation has ended. But, Sarah, perhaps before now, just really looking to redirect those on the call to provide you with their feedback, which I know is particularly important to yourself and the company. If I could please just ask you for a few closing comments just to wrap up with, that'd be great.
58:17 Sure. So, you know, I think to close, what I would really say here is that, you know, ARECOR's focus now really is on those high value opportunities with laser sharp focus there, and that's across our diabetes and obesity portfolio that we talked about in more detail today. And we very much believe we're well positioned for significant future growth. And, you know, we thank you all for your time today. And for those of you who are existing shareholders, thank you for your support. And for those that are not, but are interested in the company, then, you know, thank you for joining us today. Perfect. That's great. Sarah, David, thank you once again for updating investors this afternoon. Could I please ask investors not to close this session as you'll now be automatically redirected for the opportunity to provide your feedback in order that the management team can only better understand your views and expectations?
59:09 This will only take a few moments to complete, but I'm sure it'll be greatly valued by the company. On behalf of management team of ARECOR THERAPUITIX PLC, we would like to thank you for attending today's presentation. That now concludes today's session. So good afternoon to you all.
Follow Arecor Therapeutics PLC into a list and get an email when it puts out news.
CEO at ARECOR THERAPEUTICS PLC
CFO at ARECOR THERAPEUTICS PLC